Retatrutide Side Effects: The Trial Numbers, and the Vial That Holds Something Else
Somebody types “retatrutide side effects” into a search bar and lands on a page written as if the drug exists on a shelf. It does not. Retatrutide is an investigational molecule from Eli Lilly, five Phase 3 readouts behind it, and no approval from a regulator anywhere. That leaves the side effect question with two answer sets that have nothing to do with each other: the numbers the trials measured, and what regulators found when they opened what people injected.
The first answer set is dull in the way that real data is dull. Nausea, vomiting, diarrhea, constipation, a dose-response curve, and a discontinuation rate that climbs as the dose climbs. The second answer set includes a torn oesophagus, a state health department counting liver injuries, and a laboratory result showing a vial labelled retatrutide that contained none of it.
Retatrutide is a triple agonist. It hits GIP, GLP-1 and glucagon receptors at once, and that third receptor is why the weight loss numbers look like surgery outcomes. It is also why this molecule carries a side effect signal that its approved cousins do not.
The FDA – retatrutide cannot be compounded and is not approved
The agency’s consumer page on unapproved GLP-1 drugs, checked on October 8, 2026, states that retatrutide and cagrilintide “cannot be used in compounding under federal law.” It adds that neither one sits inside an FDA-approved drug and that the agency has not established either as safe and effective for any condition.
The enforcement record says more than that sentence does. The FDA has warned telehealth companies for marketing retatrutide to consumers, warned active pharmaceutical ingredient distributors for selling retatrutide to compounders, and warned outsourcing facilities for repackaging it. A warning letter dated September 9, 2025 to a seller called GLP-1 Solution spells out the statutory reason: retatrutide is not the subject of a USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list. Compounded retatrutide therefore sits outside the exemptions in sections 503A and 503B, which makes it an unapproved new drug.
Then comes the letter that shows what a research label sells. On August 24, 2026, the FDA wrote to Jeffrey Deng of Peak Performance Peptides in Phoenix over pppepz.com, reviewed in July 2026. The letter lists “Bac water,” “GLP-3R” (retatrutide), semaglutide, SS-31, PT-141 and tesamorelin as unapproved new drugs introduced into interstate commerce. The retatrutide pages offered 5 mg, 10 mg, 20 mg and 30 mg vials, and the site copy promised that GLP-3R “acts as a multi-receptor agonist targeting GIP, GLP-1, and glucagon receptors in research settings.” The FDA treated that sentence as evidence of intended human use, which is the reason “research use only” does not work as a shield.
A 30 mg vial of a molecule with no established human dose is not a dose. It is a label.
TRIUMPH-1 – 2,339 people, 80 weeks, and a stomach that complains
The largest human dataset on this drug landed in the New England Journal of Medicine on September 29, 2026. In TRIUMPH-1 (NCT05929066), 2,339 adults with obesity and without diabetes took 4 mg, 9 mg or 12 mg of retatrutide or a placebo once weekly for 80 weeks. The mean change in body weight was minus 17.6% at 4 mg, minus 23.7% at 9 mg and minus 25.0% at 12 mg, against minus 3.9% for placebo. Participants with knee osteoarthritis reported less pain, and participants with obstructive sleep apnea had fewer apnea-hypopnea events per hour.
The safety sentence in that abstract runs six words: “The most common adverse events were gastrointestinal.”
The granular event rates come from Lilly’s own topline release of May 21, 2026, which counted participants who stayed on treatment. At 12 mg against placebo, nausea ran 42.4% against 14.8%, diarrhea 32.0% against 13.5%, constipation 26.1% against 10.9%, and vomiting 25.3% against 4.8%. Discontinuation because of an adverse event ran 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg, against 4.9% for placebo. Roughly one in nine people on the top dose stopped because of how the drug felt.
The two weight loss figures floating around the internet, 25.0% and 28.3%, are the same trial under two different counting rules. The journal number counts all participants randomized. The company number counts participants who stayed on the drug. Both are honest. Neither is the number a person gets.
Lilly says it plans to submit a Biologics License Application for retatrutide in the first quarter of 2027, which is the cleanest way to say that no approved version exists today.
The phase 2 results – nausea at 45% on the top dose
The earlier trial is where the dose-by-dose details live, because ClinicalTrials.gov published the full results tables for the 338-participant Phase 2 study that the journal published in 2023. In the 12 mg group, 28 of 62 participants reported nausea, which is 45%, against 8 of 70 on placebo, which is 11%. Vomiting hit 12 of 62, or 19%, against 1 of 70. Constipation hit 10 of 62, or 16%, against 2 of 70. Diarrhea hit 9 of 62, or 15%, against 8 of 70.
The most useful row in that table is the one about the starting dose. At 8 mg, nausea reached 21 of 35 participants, or 60%, in the group that began at 4 mg. In the group that began at 2 mg and stepped up, the same 8 mg target produced 6 of 35, or 17%. Same destination, different first week.
The Phase 2 publication describes those events as gastrointestinal, dose-related, mostly mild to moderate, and partly blunted by a lower starting dose. It also notes dose-dependent heart rate increases that peaked at 24 weeks and declined afterward.
The dose printed on the first syringe is a side effect decision.
Dysesthesia – the signal that belongs to this molecule
Dysesthesia is an unpleasant skin sensation: tingling, burning, or a light touch that hurts. It showed up in the Phase 2 results as allodynia in 4 of 62 participants at 12 mg, with zero reports on placebo and zero at the lower doses. In the Phase 3 topline, Lilly reported dysesthesia in 5.1% of participants on 4 mg, 12.3% on 9 mg and 12.5% on 12 mg, against 0.9% on placebo. The company describes those events as generally mild to moderate, with most resolving during treatment and most participants continuing.
That pattern, climbing with the dose and sitting near zero in the placebo group, is what a real signal looks like. It is also a side effect with no approved label to read. That is part of why the phrase “retatrutide side effects” gets typed 33,100 times a month.
TGA – the vial sold as retatrutide contained none of it
Australia’s Therapeutic Goods Administration published a safety advisory on September 14, 2026 after a consumer on a product sold as retatrutide experienced uncontrollable vomiting, tore an oesophagus, and needed hospital treatment. Investigators obtained the product in its original unmarked vial and tested it.
The laboratory found undeclared semaglutide. It found no retatrutide. The semaglutide detected was approximately eight times the level found in semaglutide products the TGA has assessed and listed on the Australian Register of Therapeutic Goods.
The TGA’s chief medical adviser, Professor Robyn Langham, framed the risk as a contents question rather than a dose question: “The biggest risks with unapproved peptide products are not knowing what is in the vial, how much of or even what substance it contains, whether it is sterile, or whether it contains other contaminants or toxins.” Professor Anthony Lawler, who heads the agency, added that the safety of imported products is not assessed by the TGA at all.
A person taking that vial was not experiencing a retatrutide side effect. That person was experiencing a mislabelled semaglutide overdose, which is a different injury with a different cause.
Victoria – six cases of acute liver injury in one state
On June 19, 2026, Victoria’s Chief Health Officer, Dr Caroline McElnay, issued a health alert for health professionals and the public. Since January 2026 the department had been notified of six cases of acute liver injury in people who used an unapproved peptide product labelled Retatrutide, sold also as Reta and as R-10 or R-20, bought online, through friends, and through social media accounts.
The alert says the presentation of those cases suggests an added contaminant is contributing to the liver toxicity, and that all products carrying those labels are at risk. The symptoms to watch are tiredness, jaundice, abdominal pain, dark urine and abnormal bruising, with liver function tests showing transaminitis, raised bilirubin and coagulopathy.
An unapproved injectable with a suspected contaminant is not a weaker version of the trial drug. It is a different exposure.
A woman in her mid-20s – four injections from a life coach
The freshest documentation is a case report published October 7, 2026 in BMJ Case Reports. A woman in her mid-20s arrived with five days of persistent nausea, repeated vomiting, loose stools and markedly reduced oral intake. Blood tests, urinalysis, abdominal ultrasonography and cerebral MRI identified no alternative cause.
She did not respond to intravenous fluids, metoclopramide, ondansetron or domperidone. The exposure history, taken repeatedly and without judgement, produced the cause: four once-weekly, dose-escalated subcutaneous injections of an unverified product reported to contain retatrutide, given in a wellness setting by a self-described life coach with no medical qualification. She did not consider the injections to be medication. Symptoms improved two days after admission and resolved within a week, and a Naranjo score of 7 put causality at probable.
The authors’ advice to clinicians is the part worth stealing. Ask explicitly about injections, peptides, research chemicals, online products, and anything recommended by a non-medical wellness practitioner. The most useful question in that case was the one that went unasked on day one.
How to check a retatrutide product before it goes in
- For retatrutide, there is nothing to check. It cannot be compounded under federal law, it is not in any approved drug, and no pharmacy can make it lawfully. A seller offering it is selling an unapproved new drug.
- For compounds that can be dispensed, ask which licensed pharmacy prepared the product, and get that name in writing. A label naming a pharmacy the FDA later identifies as fraudulent is a documented pattern.
- Ask for the concentration in milligrams per millilitre as printed on the vial, plus a batch number and a third-party certificate of analysis dated to that batch.
- Treat a “research use only” sticker sold alongside dosing instructions as a warning, because the FDA treats that combination as evidence of intended drug use.
- Discard a multiple-dose vial 28 days after the first puncture, even if liquid remains, per the FDA’s own recommendation, and use a fresh needle for each injection.
Two limits belong on the record. The FDA cannot establish whether a reported adverse event came from a product or from other factors, and federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events at all, so reported counts understate what happens. And the trial numbers describe a drug manufactured under Lilly’s quality controls and given at fixed, supervised dose steps. A vial from a website shares the molecule’s name and very little else.
Our peptide tracker follows the regulatory status of the peptides state and federal regulators are actively reviewing, including the ones the FDA’s pharmacy compounding committee took up in July 2026.
Frequently asked questions
What are the most common retatrutide side effects?
Gastrointestinal events: nausea, diarrhea, constipation and vomiting, in that order of frequency in the Phase 3 topline. At 12 mg, nausea ran 42.4% against 14.8% for placebo, diarrhea 32.0% against 13.5%, constipation 26.1% against 10.9%, and vomiting 25.3% against 4.8%.
Is retatrutide approved by the FDA?
No. It is an investigational drug, and the FDA states it cannot be used in compounding under federal law. Lilly has said it plans to submit a Biologics License Application in the first quarter of 2027.
What is dysesthesia, and how often does it happen on retatrutide?
An unpleasant skin sensation such as tingling or burning. Lilly reported it in 5.1% of participants on 4 mg, 12.3% on 9 mg and 12.5% on 12 mg, against 0.9% on placebo, generally mild to moderate and mostly resolving during treatment.
How much weight did people lose in the retatrutide trials?
In TRIUMPH-1, published in September 2026, the mean change at 80 weeks was minus 17.6% on 4 mg, minus 23.7% on 9 mg and minus 25.0% on 12 mg, against minus 3.9% for placebo, counting all participants randomized. Lilly’s topline reported 28.3%, or 70.3 lb, at 12 mg among participants who stayed on treatment.
Do the retatrutide products sold online contain retatrutide?
Regulators keep finding that they do not. In September 2026 the TGA tested an unmarked vial sold as retatrutide and found no retatrutide, plus undeclared semaglutide at roughly eight times the level in semaglutide products the agency has assessed.
Can a compounded pharmacy make retatrutide if my doctor prescribes it?
No. The FDA states retatrutide cannot be used in compounding under federal law, it is not a component of an FDA-approved drug, and it does not appear on the 503A or 503B bulks lists. A prescription does not create an exemption for a bulk substance the law has not placed.
Two disclosures belong on the record. The figures quoted here describe an investigational, unapproved drug studied in trials sponsored by its manufacturer, and the compounded and black market products sold under the same name are not the drug those trials studied. Nothing on this page is a dosing instruction.
Sources: FDA, concerns with unapproved GLP-1 drugs used for weight loss, FDA warning letter 735127 to Peak Performance Peptides, August 24, 2026, FDA warning letter 715883 to GLP-1 Solution, September 9, 2025, TGA safety advisory, September 14, 2026, Victoria Department of Health alert, June 19, 2026, Buzzi et al., BMJ Case Reports, October 2026, Jastreboff et al., NEJM, September 2026, ClinicalTrials.gov, NCT05929066, ClinicalTrials.gov, NCT04881760, Eli Lilly, TRIUMPH-1 topline, May 21, 2026.